Reconciled ClinicalTrials.gov v2 Protocol Specification
| Protocol Field | Verified Registry Value |
|---|---|
| NCT Identifier | NCT03963232 |
| Consolidated Lead Sponsor | Eli Lilly and Company |
| Therapeutic Condition Cohort | Neurology, Psychiatry, and Pain |
| Clinical Trial Phase | Phase III |
| Overall Recruitment Status | COMPLETED |
| Registered Enrollment | 520 participants (ACTUAL) |
| Registered Start Date | 2019-07-30 |
| WhyStopped Classification | Not Stopped |
Named U.S. Hospital Clinical Research Sites
| Hospital Research Site | Location | Site Profile |
|---|---|---|
| Xuanwu Hospital Capital Medical University | Beijing, China | Open Hospital Dossier -> |
| Chinese PLA General Hospital | Beijing, China | Open Hospital Dossier -> |
| Guangzhou First People's Hospital | Guangzhou, China | Open Hospital Dossier -> |
| Wuhan Union Hospital | Wuhan, China | Open Hospital Dossier -> |
Related Filings Across Meru Platforms
Verified cross-ledger federal filings for Eli Lilly and Company across sibling Meru public-data platforms.
Search related sites and sponsors in the Interactive Directory, explore Neurology, Psychiatry, and Pain Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.